Hospital Pharmacy - June 2019 - 143
Defitelio was proven to improve survival at Day +100 in
adult and pediatric patients consistently across 3 studies1
SURVIVAL AT DAY +100 POST HSCT WITH DEFITELIO ACROSS
STUDIES IN ADULT AND PEDIATRIC PATIENTS 1
Survival at Day +100
post HSCT with Defitelio (%)
60
50
95% CI:
29%, 48%
95% CI:
33%, 55%
40
30
20
38
44
95% CI:
40%, 51%
45
10
0
STUDY 1
(n =102)
STUDY 2
(n =75)
EXPECTED DAY +100 SURVIVAL
WITH SUPPORTIVE CARE
21% TO 31%
STUDY 3
The efficacy of Defitelio was
investigated in 3 studies:
2 prospective clinical trials
(Study 1 and Study 2) and
an expanded access study
(Study 3), which included
528 adult and pediatric
patients with hepatic VOD
with renal or pulmonary
dysfunction following HSCT.
Patients received Defitelio at
a dose of 6.25 mg/kg every
6 hours.
(n =351)
Based on published reports and analyses of patientlevel data for individuals with hepatic VOD with renal
or pulmonary dysfunction who received supportive
care or interventions other than Defitelio.1
Warnings and Precautions
Hemorrhage
Defitelio may increase the risk of bleeding in patients with VOD after HSCT. Do not initiate Defitelio
in patients with active bleeding. Monitor patients on Defitelio for signs of bleeding. If bleeding occurs,
withhold or discontinue Defitelio.
Concomitant systemic anticoagulant or fibrinolytic therapy may increase the risk of bleeding and should
be discontinued prior to Defitelio treatment. Consider delaying Defitelio administration until the effects
of the anticoagulant have abated.
Hypersensitivity Reactions
Hypersensitivity reactions including rash, urticaria, and angioedema have occurred in less than 2% of
patients treated with Defitelio. One case of an anaphylactic reaction was reported in a patient who
had previously received Defitelio. Monitor patients for hypersensitivity reactions, especially if there is
a history of previous exposure. If a severe hypersensitivity reaction occurs, discontinue Defitelio, treat
according to the standard of care, and monitor until symptoms resolve.
Most Common Adverse Reactions
The most common adverse reactions (incidence ≥10% and independent of causality) with Defitelio
treatment were hypotension, diarrhea, vomiting, nausea, and epistaxis.
Please see following pages for Brief Summary of
Prescribing Information.
Reference: 1. Defitelio [package insert]. Palo Alto, CA: Jazz Pharmaceuticals.
Hospital Pharmacy - June 2019
Table of Contents for the Digital Edition of Hospital Pharmacy - June 2019
TOC/Verso
The Future CPOE Workflow: Augmenting Clinical Decision Support With Pharmacist Expertise
Contributing Factors to Perceptions of Residents’ Statistical Abilities
Mix-Ups Between Epidural Analgesia and IV Antibiotics in Labor and Delivery Units Continue to Cause Harm
Acute Hepatotoxicity After High-Dose Cytarabine for the Treatment of Relapsed Acute Myeloid Leukemia: A Case Report
Baloxavir Marboxil
Integration of an Academic Medical Center and a Large Health System: Implications for Pharmacy
The Culture of Carbapenem Overconsumption. : Where Does It Begin? Results of a Single-Center Survey
Clinical Pharmacist Impact on Intensive Care Unit Delirium: Intervention and Monitoring
A Case Report of Hypertensive Emergency and Intracranial Hemorrhage Due to Intracavernosal Phenylephrine
Stability of Meropenem After Reconstitution for Administration by Prolonged Infusion
Hypoglycemia Associated With Insulin Use During Treatment of Hyperkalemia Among Emergency Department Patients
Impact of Implementing Smart Infusion Pumps in an Intensive Care Unit in Mexico: A Pre-Post Cost Analysis Based on Intravenous Solutions Consumption
Hospital Pharmacy - June 2019 - Cover1
Hospital Pharmacy - June 2019 - Cover2
Hospital Pharmacy - June 2019 - 137
Hospital Pharmacy - June 2019 - 138
Hospital Pharmacy - June 2019 - 139
Hospital Pharmacy - June 2019 - 140
Hospital Pharmacy - June 2019 - 141
Hospital Pharmacy - June 2019 - 142
Hospital Pharmacy - June 2019 - 143
Hospital Pharmacy - June 2019 - 144
Hospital Pharmacy - June 2019 - 145
Hospital Pharmacy - June 2019 - 146
Hospital Pharmacy - June 2019 - TOC/Verso
Hospital Pharmacy - June 2019 - 148
Hospital Pharmacy - June 2019 - The Future CPOE Workflow: Augmenting Clinical Decision Support With Pharmacist Expertise
Hospital Pharmacy - June 2019 - 150
Hospital Pharmacy - June 2019 - 151
Hospital Pharmacy - June 2019 - 152
Hospital Pharmacy - June 2019 - Contributing Factors to Perceptions of Residents’ Statistical Abilities
Hospital Pharmacy - June 2019 - 154
Hospital Pharmacy - June 2019 - Mix-Ups Between Epidural Analgesia and IV Antibiotics in Labor and Delivery Units Continue to Cause Harm
Hospital Pharmacy - June 2019 - 156
Hospital Pharmacy - June 2019 - 157
Hospital Pharmacy - June 2019 - 158
Hospital Pharmacy - June 2019 - 159
Hospital Pharmacy - June 2019 - Acute Hepatotoxicity After High-Dose Cytarabine for the Treatment of Relapsed Acute Myeloid Leukemia: A Case Report
Hospital Pharmacy - June 2019 - 161
Hospital Pharmacy - June 2019 - 162
Hospital Pharmacy - June 2019 - 163
Hospital Pharmacy - June 2019 - 164
Hospital Pharmacy - June 2019 - Baloxavir Marboxil
Hospital Pharmacy - June 2019 - 166
Hospital Pharmacy - June 2019 - 167
Hospital Pharmacy - June 2019 - 168
Hospital Pharmacy - June 2019 - 169
Hospital Pharmacy - June 2019 - Integration of an Academic Medical Center and a Large Health System: Implications for Pharmacy
Hospital Pharmacy - June 2019 - 171
Hospital Pharmacy - June 2019 - 172
Hospital Pharmacy - June 2019 - 173
Hospital Pharmacy - June 2019 - 174
Hospital Pharmacy - June 2019 - The Culture of Carbapenem Overconsumption. : Where Does It Begin? Results of a Single-Center Survey
Hospital Pharmacy - June 2019 - 176
Hospital Pharmacy - June 2019 - 177
Hospital Pharmacy - June 2019 - 178
Hospital Pharmacy - June 2019 - 179
Hospital Pharmacy - June 2019 - Clinical Pharmacist Impact on Intensive Care Unit Delirium: Intervention and Monitoring
Hospital Pharmacy - June 2019 - 181
Hospital Pharmacy - June 2019 - 182
Hospital Pharmacy - June 2019 - 183
Hospital Pharmacy - June 2019 - 184
Hospital Pharmacy - June 2019 - 185
Hospital Pharmacy - June 2019 - A Case Report of Hypertensive Emergency and Intracranial Hemorrhage Due to Intracavernosal Phenylephrine
Hospital Pharmacy - June 2019 - 187
Hospital Pharmacy - June 2019 - 188
Hospital Pharmacy - June 2019 - 189
Hospital Pharmacy - June 2019 - Stability of Meropenem After Reconstitution for Administration by Prolonged Infusion
Hospital Pharmacy - June 2019 - 191
Hospital Pharmacy - June 2019 - 192
Hospital Pharmacy - June 2019 - 193
Hospital Pharmacy - June 2019 - 194
Hospital Pharmacy - June 2019 - 195
Hospital Pharmacy - June 2019 - 196
Hospital Pharmacy - June 2019 - Hypoglycemia Associated With Insulin Use During Treatment of Hyperkalemia Among Emergency Department Patients
Hospital Pharmacy - June 2019 - 198
Hospital Pharmacy - June 2019 - 199
Hospital Pharmacy - June 2019 - 200
Hospital Pharmacy - June 2019 - 201
Hospital Pharmacy - June 2019 - 202
Hospital Pharmacy - June 2019 - Impact of Implementing Smart Infusion Pumps in an Intensive Care Unit in Mexico: A Pre-Post Cost Analysis Based on Intravenous Solutions Consumption
Hospital Pharmacy - June 2019 - 204
Hospital Pharmacy - June 2019 - 205
Hospital Pharmacy - June 2019 - 206
Hospital Pharmacy - June 2019 - 207
Hospital Pharmacy - June 2019 - 208
Hospital Pharmacy - June 2019 - Cover3
Hospital Pharmacy - June 2019 - Cover4
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_december2020
https://www.nxtbook.com/nxtbooks/sage/psychologicalscience_demo
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_october2020
https://www.nxtbook.com/nxtbooks/sage/fai_202009
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_august2020
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_june2020
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_april2020
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_february2020
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_december2019
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_october2019
https://www.nxtbook.com/nxtbooks/sage/fai_201909
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_july2019
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_june2019
https://www.nxtbook.com/nxtbooks/sage/canadianpharmacistsjournal_05062019
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_april2019
https://www.nxtbook.com/nxtbooks/sage/sri_supplement_201903
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_february2019
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_december2018
https://www.nxtbook.com/nxtbooks/sage/tec_20180810
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_october2018
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_julyaugust2018
https://www.nxtbook.com/nxtbooks/sage/fai_201807
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_june2018
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_april2018
https://www.nxtbook.com/nxtbooks/sage/sri_supplement_201803
https://www.nxtbook.com/nxtbooks/sage/slas_discovery_201712
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_february2018
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_december2017
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_november2017
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_october2017
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_september2017
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_julyaugust2017
https://www.nxtbook.com/nxtbooks/sage/fai_supplement_201709
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_june2017
https://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_may2017
https://www.nxtbook.com/nxtbooks/sage/fai_201706
https://www.nxtbook.com/nxtbooks/sage/fai_201607
https://www.nxtbookmedia.com